Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand

References

• Sheridan J, Butler R, Wilkins C, et al. Legal piperazine-containing party pills – a new trend in substance misuse. Drug Alcohol Rev 2007; 26: 335–343
   PubMed Web of Science ®Google Scholar
• Wilkins C, Girling M, Sweetsur P. The prevalence of use, dependency and harms of legal ‘party pills’ containing benzylpiperazine (BZP) and trifluorophenylmethylpiperazine (TFMPP) in New Zealand. J Subst Use 2007; 12: 213–225
   Google Scholar
• New Zealand Herald. Restraints on party pills delayed. 1 April, 2005
   Google Scholar
• Nicholson T. Prevalence of use, epidemiology and toxicity of ‘herbal party pills’ among those presenting to the emergency department. Emerg Med Australasia 2006; 18: 180–184
   PubMedGoogle Scholar
• Baumann M, Clark R, Budzynski A, et al. Effects of ‘Legal X’ piperazine analogs on dopamine and serotonin release in rat brain. Ann NY Acad Sci 2004; 1025: 189–197
   PubMed Web of Science ®Google Scholar
• McCandless D. Clubbers snap up new legal high. Guardian 13 December, 2005
   Google Scholar
• Kirby T. Funk pills: getting on a ‘legal high'. Independent 30 May, 2006
   Google Scholar
• Vince G. Legally high. New Scientist 2006; 191(2571)40–45
   Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) & Europol. Europol – EMCDDA Joint report on a new psychoactive substance: 1-benzylpiperazine (BZP) (in accordance with Article 5 of Council Decision 2005/387/JHA on information exchange, risk assessment and control of new psychoactive substances. Lisbon, 2005. Available at: http://www.emcdda.europa.eu/?nnodeid=1346 (accessed 7 March 2008)
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. Risk assessment report of a new psychoactive substance: 1-benzylpiperazine (BZP) (in accordance with Article 6 of Council Decision 2005/387/JHA on information exchange, risk assessment and control of new psychoactive substances). Lisbon, 2007. Available at: http://register.consilium.europa.eu/pdf/en/07/st10/st10458.en07.pdf (accessed 7 March 2008)
   Google Scholar
• Bye C, Munro-Faure A, Peck A, et al. A comparison of the effects of l-benzylpiperazine on human performance tests. Eur J Clin Pharmacol 1973; 6: 163–169
   PubMed Web of Science ®Google Scholar
• Campbell H, Cline W, Evans M, et al. Comparison of the effects of dexamethamphetamine and l-benzylpiperazine in former addicts. Eur J Clin Pharmacol 1972; 6: 170–176
   Web of Science ®Google Scholar
• Expert Advisory Committee on Drugs, The Expert Advisory Committee on Drugs (EACD). Advice to the Minister on: Benzylpiperazibe (BZP), April. EACD: Wellington, 2004
   Google Scholar
• Gee P, Richardson S, Woltersdorf W, et al. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. NZ Med J 2005; 118: 1784–1794
   PubMedGoogle Scholar
• GuruGardener. Herbal highs – Party pills, undated. Available at: http://www.gurugardener.co.nz/herbal%20highs%20selection.htm (accessed 10 August 2007)
   Google Scholar
• Alansari M, Hamilton D. Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report. NZ Med J 2006; 119: 1959–1961
   Google Scholar
• Wilkins C, Girling M, Sweetsur P, et al. Legal party pill use in New Zealand: Prevalence of use, availability, health harms and ‘gateway effects’ of benzylpiperazine (BZP) and triflourophenylmethylpiperazine (TFMPP), June. Centre for Social and Health Outcomes Research and Evaluation (SHORE) & Te Ropu Whariki, Massey University, Auckland 2006
   Google Scholar
• Hall W, Hando J. Route of administration and adverse effects of amphetamine use among young adults in Sydney, Australia. Drug Alcohol Rev 1994; 13: 277–284
   PubMedGoogle Scholar
• Hando J, Topp L, Hall W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug Alcohol Depend 1997; 46: 105–113
   PubMed Web of Science ®Google Scholar
• Topp L, Hando J, Dillon P, et al. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999; 55: 105–115
   PubMed Web of Science ®Google Scholar
• TOXINZ. TOXINZ is an Internet database containing information regarding toxic compounds and the management of poisoned patients, undated. Available at: http://www.toxinz.com/ (accessed 10 August 2007)
   Google Scholar
• Drug Enforcement Administration (DEA). Department of Justice, Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final ruling. Fed Register 2004; 69: 12794–12797
   PubMedGoogle Scholar
• Hon Jim Anderton. BZP to be banned. 2007; 28 June 2007. Available at: http://www.progressive.org.nz/modules.php?name=News&file=article&sid=2768 (accessed 7 March 2008)
   Google Scholar
• Vice President Frattini. New Commission proposal to strengthen control of synthetic drug BZP 2007, 17 July 2007. Available at: http://europa.eu/rapid/pressReleasesAction.do?reference=IP/07/1103&format=HTML&aged=0& language=ENlguiLanguage=en (accessed 7 March 2008)
   Google Scholar